8/11/2014 6:15:44 AM
Ex-Merck Exec Appointed New President And CEO Of Medivir AB
August 11, 2014
By Krystle Vermes, BioSpace.com Breaking News Staff
Today, Medivir AB (MVRBF) announced that its board of directors has appointed Niklas Prager to become the new CEO and president of the company beginning Sept. 1. Prager will bring years of experience to the table when he fills the positions left vacant by Maris Hartmanis.
In the past, Prager has worked for Merck and Co. in both the U.S. and Sweden. Additionally, he has filled the role of CEO of Pfizer, Envirotainer AB and Qbtech AB.
Prager was elected to the board of directors of Medivir in May 2014. As a result, he is extremely familiar with the company’s operations heading into his new position as CEO and president of the company.
”I am delighted to welcome Niklas to the position of CEO of Medivir,” said Birgitta Stymne Göransson, Chairman of the Board of Directors of Medivir. “The Board has carried out an extensive recruitment process during the spring which involved several highly qualified candidates. Niklas has a background in both biotech and big pharma, and his large network of contacts in the Swedish and international pharmaceutical industries make him an ideal choice for us. Niklas will in particular be able to contribute and strengthen Medivir in the important areas of strategic business development and commercialization.”
As Prager transitions into his new roles at the company, he will be leaving its board of directors. However, he will be working closely with the board as the CEO and president of the business.
“I look forward to taking up the position as CEO of Medivir,” said Prager. “Medivir is an attractive company in an exciting phase of its development following the successful market introduction of Simeprevir. Together with the Board, the highly skilled research team and all other Medivir employees, I will be focusing on further value creation and enhanced visibility of Medivir’s potential. An update of Medivir’s strategic plan is the number one priority, and work on this is already well under way.”
Medivir’s research and development segment is currently focused on infectious diseases, bone related disorders, neuropathic pain and oncology. The experience that Prager brings to the company will help it grow and excel in its areas of focus.
Prager holds a Degree of Master of Science in Business Administration and Economics from the Stockholm School of Economics.
Read more recent executive staff news.
comments powered by